Back to search
FDAFDA · Food and drugs·Recall number D-1334-2022

Azacitidine for Injection 100mg/vial Lyophilized Powder, Rx Only, Mfd. in Romania By: Sindan Pharma SRL For BluePoint Laboratories, NDC 68001-313-56

Published August 17, 2022 · Recall initiated: July 22, 2022

Summary

FDA records drug Class III recall D-1334-2022, published August 17, 2022 and initiated July 22, 2022. Recalling firm: Teva Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 4162 cartons; Lot: Lot: FE22001A, Exp 01/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification.

What to do

Voluntary: Firm initiated · Letter

Get an email if AZACITIDINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
AZACITIDINE
Manufacturer
Teva Pharmaceuticals USA Inc
Distributor
Distributed in Ohio
UPC
0368001313568
Lot
Lot: FE22001A, Exp 01/2024
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Azacitidine for Injection 100mg/vial Lyophilized Powder, Rx Only, Mfd. in Romania By: Sindan Pharma SRL For BluePoint Laboratories, NDC 68001-313-56 recalled?

Yes. FDA published recall D-1334-2022 on August 17, 2022. Reported hazard: Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: AZACITIDINE. UPC: 0368001313568.